Результаты поиска авторов

1

Chronic Lung Disease after Premature Birth по Vivek Subbiah

Опубликовано 2008

Полный текст
Carta

Добавить в Избранное

Сохранить в:
2

The next generation of evidence-based medicine по Vivek Subbiah

Опубликовано 2023

Полный текст Полный текст
Revisão

Добавить в Избранное

Сохранить в:
3

Tissue-agnostic cancer therapies: promise, reality, and the path forward по Vivek Subbiah

Опубликовано 2025

Полный текст
Artigo

Добавить в Избранное

Сохранить в:
4

Challenging Standard-of-Care Paradigms in the Precision Oncology Era по Vivek Subbiah, Razelle Kurzrock

Опубликовано 2018

Полный текст Полный текст
Revisão

Добавить в Избранное

Сохранить в:
5

Managing Cancer Care during the COVID-19 Pandemic and Beyond по Omar Alhalabi, Vivek Subbiah

Опубликовано 2020

Полный текст Полный текст
Artigo

Добавить в Избранное

Сохранить в:
6

Universal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer: Genomics Is the Diagnosis по Vivek Subbiah, Razelle Kurzrock

Опубликовано 2023

Полный текст
Artigo

Добавить в Избранное

Сохранить в:
7

Tumor-agnostic drug development in dMMR/MSI-H solid tumors по Deepak Bhamidipati, Vivek Subbiah

Опубликовано 2023

Полный текст Полный текст
Revisão

Добавить в Избранное

Сохранить в:
8

Clinical development and management of adverse events associated with FGFR inhibitors по Vivek Subbiah, Srđan Verstovšek

Опубликовано 2023

Полный текст Полный текст
Revisão

Добавить в Избранное

Сохранить в:
9

Advances in Targeting RET-Dependent Cancers по Vivek Subbiah, Gilbert J. Cote

Опубликовано 2020

Полный текст
Revisão

Добавить в Избранное

Сохранить в:
10

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy по Mohamed A. Gouda, Vivek Subbiah

Опубликовано 2023

Полный текст
Revisão

Добавить в Избранное

Сохранить в:
11

Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E–Positive Adult and Pediatric Solid Tumors по Mohamed A. Gouda, Vivek Subbiah

Опубликовано 2023

Полный текст Полный текст
Revisão

Добавить в Избранное

Сохранить в:
12

Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers по Mohamed A. Gouda, Vivek Subbiah

Опубликовано 2023

Полный текст Полный текст
Revisão

Добавить в Избранное

Сохранить в:
13

Clinical Development of BRAF plus MEK Inhibitor Combinations по Vivek Subbiah, Christina S. Baik, John M. Kirkwood

Опубликовано 2020

Полный текст Полный текст
Revisão

Добавить в Избранное

Сохранить в:
14

From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm по Jacob J. Adashek, Vivek Subbiah, Razelle Kurzrock

Опубликовано 2020

Полный текст Полный текст
Revisão

Добавить в Избранное

Сохранить в:
15

Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives по Vivek Subbiah, Hubert H. Chuang, Dhiraj Gambhire, Kalevi Kairemo

Опубликовано 2017

Полный текст Полный текст
Artigo

Добавить в Избранное

Сохранить в:
16

The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians по Vivek Subbiah, David B. Solit, Timothy A. Chan, Razelle Kurzrock

Опубликовано 2020

Полный текст
Editorial

Добавить в Избранное

Сохранить в:
17

State-of-the-Art Strategies for Targeting RET-Dependent Cancers по Vivek Subbiah, Dong Yang, Vamsidhar Velcheti, Alexander Drilon, Funda Meric‐Bernstam

Опубликовано 2020

Полный текст
Revisão

Добавить в Избранное

Сохранить в:
18

The abscopal effect in patients with cancer receiving immunotherapy по Blessie Elizabeth Nelson, Jacob J. Adashek, Steven H. Lin, Vivek Subbiah

Опубликовано 2023

Полный текст Полный текст
Revisão

Добавить в Избранное

Сохранить в:
19

From dominance to decline: can we reverse the trend in small molecule and TKI cancer therapies? по Denis Horgan, Paul Hofman, Daniel J. Schneider, Umberto Malapelle, Vivek Subbiah

Опубликовано 2025

Полный текст
Revisão

Добавить в Избранное

Сохранить в:
20

The emerging role of PI3K inhibitors for solid tumour treatment and beyond по Carmen Belli, Matteo Repetto, Santosh Anand, Camillo Porta, Vivek Subbiah, Giuseppe Curigliano

Опубликовано 2023

Полный текст
Revisão

Добавить в Избранное

Сохранить в:

Chronic Lung Disease after Premature Birth по Vivek Subbiah

The next generation of evidence-based medicine по Vivek Subbiah

Tissue-agnostic cancer therapies: promise, reality, and the path forward по Vivek Subbiah

Challenging Standard-of-Care Paradigms in the Precision Oncology Era по Vivek Subbiah, Razelle Kurzrock

Managing Cancer Care during the COVID-19 Pandemic and Beyond по Omar Alhalabi, Vivek Subbiah

Universal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer: <i>Genomics Is the Diagnosis</i> по Vivek Subbiah, Razelle Kurzrock

Tumor-agnostic drug development in dMMR/MSI-H solid tumors по Deepak Bhamidipati, Vivek Subbiah

Clinical development and management of adverse events associated with FGFR inhibitors по Vivek Subbiah, Srđan Verstovšek

Advances in Targeting RET-Dependent Cancers по Vivek Subbiah, Gilbert J. Cote

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy по Mohamed A. Gouda, Vivek Subbiah

Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for <i>BRAF</i> V600E–Positive Adult and Pediatric Solid Tumors по Mohamed A. Gouda, Vivek Subbiah

Precision oncology with selective RET inhibitor selpercatinib in <i>RET</i>-rearranged cancers по Mohamed A. Gouda, Vivek Subbiah

Clinical Development of BRAF plus MEK Inhibitor Combinations по Vivek Subbiah, Christina S. Baik, John M. Kirkwood

From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm по Jacob J. Adashek, Vivek Subbiah, Razelle Kurzrock

Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives по Vivek Subbiah, Hubert H. Chuang, Dhiraj Gambhire, Kalevi Kairemo

The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians по Vivek Subbiah, David B. Solit, Timothy A. Chan, Razelle Kurzrock

State-of-the-Art Strategies for Targeting <i>RET</i>-Dependent Cancers по Vivek Subbiah, Dong Yang, Vamsidhar Velcheti, Alexander Drilon, Funda Meric‐Bernstam

The abscopal effect in patients with cancer receiving immunotherapy по Blessie Elizabeth Nelson, Jacob J. Adashek, Steven H. Lin, Vivek Subbiah

From dominance to decline: can we reverse the trend in small molecule and TKI cancer therapies? по Denis Horgan, Paul Hofman, Daniel J. Schneider, Umberto Malapelle, Vivek Subbiah

The emerging role of PI3K inhibitors for solid tumour treatment and beyond по Carmen Belli, Matteo Repetto, Santosh Anand, Camillo Porta, Vivek Subbiah, Giuseppe Curigliano

Результаты поиска - Vivek Subbiah

Chronic Lung Disease after Premature Birth по Vivek Subbiah

The next generation of evidence-based medicine по Vivek Subbiah

Tissue-agnostic cancer therapies: promise, reality, and the path forward по Vivek Subbiah

Challenging Standard-of-Care Paradigms in the Precision Oncology Era по Vivek Subbiah, Razelle Kurzrock

Managing Cancer Care during the COVID-19 Pandemic and Beyond по Omar Alhalabi, Vivek Subbiah

Universal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer: <i>Genomics Is the Diagnosis</i> по Vivek Subbiah, Razelle Kurzrock

Tumor-agnostic drug development in dMMR/MSI-H solid tumors по Deepak Bhamidipati, Vivek Subbiah

Clinical development and management of adverse events associated with FGFR inhibitors по Vivek Subbiah, Srđan Verstovšek

Advances in Targeting RET-Dependent Cancers по Vivek Subbiah, Gilbert J. Cote

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy по Mohamed A. Gouda, Vivek Subbiah

Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for <i>BRAF</i> V600E–Positive Adult and Pediatric Solid Tumors по Mohamed A. Gouda, Vivek Subbiah

Precision oncology with selective RET inhibitor selpercatinib in <i>RET</i>-rearranged cancers по Mohamed A. Gouda, Vivek Subbiah

Clinical Development of BRAF plus MEK Inhibitor Combinations по Vivek Subbiah, Christina S. Baik, John M. Kirkwood

From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm по Jacob J. Adashek, Vivek Subbiah, Razelle Kurzrock

Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives по Vivek Subbiah, Hubert H. Chuang, Dhiraj Gambhire, Kalevi Kairemo

The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians по Vivek Subbiah, David B. Solit, Timothy A. Chan, Razelle Kurzrock

State-of-the-Art Strategies for Targeting <i>RET</i>-Dependent Cancers по Vivek Subbiah, Dong Yang, Vamsidhar Velcheti, Alexander Drilon, Funda Meric‐Bernstam

The abscopal effect in patients with cancer receiving immunotherapy по Blessie Elizabeth Nelson, Jacob J. Adashek, Steven H. Lin, Vivek Subbiah

From dominance to decline: can we reverse the trend in small molecule and TKI cancer therapies? по Denis Horgan, Paul Hofman, Daniel J. Schneider, Umberto Malapelle, Vivek Subbiah

The emerging role of PI3K inhibitors for solid tumour treatment and beyond по Carmen Belli, Matteo Repetto, Santosh Anand, Camillo Porta, Vivek Subbiah, Giuseppe Curigliano

Инструменты поиска:

Связанные темы